NCT06772987Completed
NQ TMS for MDD Therapy Using 1 Day x 3 Sessions Protocol for Adult Patient
Safety and Efficacy of an Accelerated, Rectangular Waveform rTMS Protocol in Treatment of Adults With Major Depressive Disorder
Source: ClinicalTrials.gov · Last updated 13 May 2025
Brief summary (registry, in English)
Transcranial Magnetic Stimulation (TMS) Therapy is a non-invasive procedure that uses magnetic pulses to stimulate the cortex (brain) to treat Major Depressive Disorder (MDD). Currently established therapy uses one 19-minute treatment session per day for 5 days per week for 6 weeks, for a total of 30 treatment sessions. The goal of this clinical trial is to evaluate the safety and effectiveness of an accelerated but shortened TMS dosing regimen for adults with MDD aged 22-85. Participants in this study will be subjected to the same 19-minutes treatment session, but three times on the same day, and only for one day. This will greatly reduce the logistical burden of completing the therapy regime.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 50 (actual)
- First submitted
- 9 Jan 2025
- Start date
- 16 Jan 2025
- Primary completion date
- 6 May 2025
- Lead sponsor
- NeuroQore Inc.
- Diseases
- Depression
- NCT number
- NCT06772987
What you commit to
- Study type: Interventional
- Participants enrolled: 50
- From 16 Jan 2025 to the primary completion date, 6 May 2025
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- Any medical conditions that would preclude the use of rTMS to treat depression.
- Any conditions that would prevent the ability to undergo MRI testing.
- History of epilepsy, seizure(s), or a seizure disorder as determined by the principal investigator based on a medical history obtained from the patient and/or others authorized to provide such history, combined with a brief screening instrument.
- Diagnosis of bipolar or psychotic disorder
- As determined by the Principal Investigator, subjects with cognitive impairment according to either the medical history obtained from the patient and/or a reliable secondary source, or the results of the Montreal Cognitive Assessment (MoCA) performed during screening.
Lab values
- Pregnancy as determined by serum/urine pregnancy test
Other
- Active substance abuse
- Considered to be at moderate-high risk of suicide according to the CSSRS assessment (i.e., Answers YES to Question 3 and NO to Question 6; or answers YES to Question 4, 5, or 6)
Who the study is looking for
- Males or females aged 22-85.
- Current diagnosis of major depressive disorder according to the criteria defined in the current Diagnosis and Statistical Manual of Mental Disorders (DSM-V) without psychotic features.
- Failed to receive satisfactory improvement from prior antidepressant medication in the current episode.
- MADRS score \> 20 at baseline and immediately prior to the day of treatment.
- Agrees to adhere to the study treatment and follow-up schedule.
- Willingness to remain on stable medications during rTMS therapy.
- Fluent in English.
Age in the registry: 22 years to 85 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| LGTC Group Coordinator of this site? Confirm its status | San Jose | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.